Last reviewed · How we verify
Strategic Science & Technologies, LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Oral Sildenafil 50 mg | Oral Sildenafil 50 mg | marketed | ||||
| SST-0225 | SST-0225 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| SST-0225 Topical Ibuprofen Cream | SST-0225 Topical Ibuprofen Cream | phase 3 | NSAID | Pain Management |
Therapeutic area mix
- Diabetes · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Novartis · 2 shared drug classes
- Allergan · 2 shared drug classes
- Apsen Farmaceutica S.A. · 2 shared drug classes
- AstraZeneca · 2 shared drug classes
- Pfizer · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Strategic Science & Technologies, LLC:
- Strategic Science & Technologies, LLC pipeline updates — RSS
- Strategic Science & Technologies, LLC pipeline updates — Atom
- Strategic Science & Technologies, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Strategic Science & Technologies, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/strategic-science-technologies-llc. Accessed 2026-06-10.